van Deventer SJ - Search Results

1

Immunohistochemical analysis of inflammation in primary sclerosing cholangitis.

Ponsioen CY, Kuiper H, Ten Kate FJ, van Milligen de Wit M, van Deventer SJ, Tytgat GN. Ponsioen CY, et al. Among authors: van milligen de wit m, van deventer sj. Eur J Gastroenterol Hepatol. 1999 Jul;11(7):769-74. doi: 10.1097/00042737-199907000-00015. Eur J Gastroenterol Hepatol. 1999. PMID: 10445798

2

Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies.

van Milligen de Wit AW, van Deventer SJ, Tytgat GN. van Milligen de Wit AW, et al. Among authors: van deventer sj. Am J Gastroenterol. 1995 Jun;90(6):893-900. Am J Gastroenterol. 1995. PMID: 7771416 Review.

3

Lexipafant (BB-882), a platelet activating factor receptor antagonist, ameliorates mucosal inflammation in an animal model of colitis.

Meenan J, Grool TA, Hommes DW, Dijkhuizen S, ten Kate FJ, Wood M, Whittaker M, Tytgat GN, van Deventer SJ. Meenan J, et al. Among authors: van deventer sj. Eur J Gastroenterol Hepatol. 1996 Jun;8(6):569-73. doi: 10.1097/00042737-199606000-00014. Eur J Gastroenterol Hepatol. 1996. PMID: 8823572

4

Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?

van Milligen de Wit AW, Kuiper H, Camoglio L, van Bracht J, Jones EA, Tytgat GN, van Deventer SJ. van Milligen de Wit AW, et al. Among authors: van deventer sj, van bracht j. Eur J Gastroenterol Hepatol. 1999 Feb;11(2):129-36. doi: 10.1097/00042737-199902000-00013. Eur J Gastroenterol Hepatol. 1999. PMID: 10102223 Clinical Trial.

5

A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis.

Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, ten Kate F, van Deventer SJ. Hommes DW, et al. Among authors: van deventer sj, van der spek m. J Clin Gastroenterol. 2008 May-Jun;42(5):522-6. doi: 10.1097/MCG.0b013e3181662426. J Clin Gastroenterol. 2008. PMID: 18344886 Clinical Trial.

6

CD4 antibody treatment in Crohn's disease.

Stronkhorst A, Tytgat GN, van Deventer SJ. Stronkhorst A, et al. Among authors: van deventer sj. Scand J Gastroenterol Suppl. 1992;194:61-5. doi: 10.3109/00365529209096029. Scand J Gastroenterol Suppl. 1992. PMID: 1298050

7

Intestinal endotoxemia. Clinical significance.

van Deventer SJ, ten Cate JW, Tytgat GN. van Deventer SJ, et al. Gastroenterology. 1988 Mar;94(3):825-31. doi: 10.1016/0016-5085(88)90261-2. Gastroenterology. 1988. PMID: 3276576 Review. No abstract available.

8

Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases.

Bruin KF, Hommes DW, Jansen J, Tytgat GN, Wouter ten Cate J, van Deventer SJ. Bruin KF, et al. Among authors: van deventer sj. Eur J Gastroenterol Hepatol. 1995 Aug;7(8):791-5. Eur J Gastroenterol Hepatol. 1995. PMID: 7496871

9

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. van Dullemen HM, et al. Among authors: van deventer sj. Gastroenterology. 1995 Jul;109(1):129-35. doi: 10.1016/0016-5085(95)90277-5. Gastroenterology. 1995. PMID: 7797011 Clinical Trial.

10

Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability-increasing protein.

Monajemi H, Meenan J, Lamping R, Obradov DO, Radema SA, Trown PW, Tytgat GN, Van Deventer SJ. Monajemi H, et al. Among authors: van deventer sj. Gastroenterology. 1996 Mar;110(3):733-9. doi: 10.1053/gast.1996.v110.pm8608882. Gastroenterology. 1996. PMID: 8608882

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

436 results

Search Page

Filters